Bao-shan Hu

发表

Retraction Note to: Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy

Xu He, Yong Li, Wei Zhao, 2014, Medical Oncology.

RETRACTED ARTICLE: Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy

Xu He, Yong Li, Wei Zhao, 2014, Medical Oncology.

The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.

Xu He, Yong Li, Wei Zhao, 2013, Asian Pacific journal of cancer prevention : APJCP.

Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma

Kai Chen, Meixiao Zhan, Xu He, 2017, Oncology letters.

Transhepatic arterial chemoembolizations with lobaplatin-eluting microspheres for the treatment of unresectable hepatocellular carcinoma

Xu He, Yong Li, Li-Gong Lu, 2018 .

An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients

Xu He, Yong Li, Li-Gong Lu, 2016, Hepatology International.

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib

Meixiao Zhan, Xu He, Yong Li, 2014, Medical Oncology.

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

Xu He, Yong Li, Wei Zhao, 2015, Journal of Cancer Research and Clinical Oncology.

Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Ligong Lu, Meixiao Zhan, Xu He, 2014, Journal of vascular and interventional radiology : JVIR.

Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases

C. Liang, Zaiyi Liu, Meng Li, 2016, Medicine.

Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma

Meixiao Zhan, Xu He, Yong Li, 2014, Tumor Biology.

Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas

Yong Li, Li-Gong Lu, Bao-shan Hu, 2013, Chinese medical journal.

Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.

Meixiao Zhan, Jiaping Li, Xu He, 2014, Asian Pacific journal of cancer prevention : APJCP.

Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma

Xu He, Yong Li, Wei Zhao, 2013, Medical Oncology.

Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial

Xu He, Yong Li, Wei Zhao, 2015, Oncology.